Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: Clinical and mechanistic aspects

British Journal of Cancer

Volumn 96, Issue 2, 2007, Pages 362-372

  Shan, S J C ^a,b   Scorilas, A ^c   Katsaros, D ^d   Diamandis, E P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Biomarker; Gene regulation; Human kallikrein 6; Human kallikreins; Ovarian cancer; Serine protease

Indexed keywords

KALLIKREIN; KALLIKREIN 6; MESSENGER RNA; MONOCLONAL ANTIBODY; STEROID HORMONE; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENOMICS; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; LABELING INDEX; OVARY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; UPREGULATION; VALIDATION PROCESS;

5' UNTRANSLATED REGIONS; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TISSUE KALLIKREINS; TRANSCRIPTION, GENETIC;

EID: 33846473583     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603556     Document Type: Article

References (61)

1. Becker C, Noldus J, Diamandis E, Lilja H (2004) The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev Clin Lab Sci 38: 357-399
2. Bello MJ, Rey JA (1990) Chromosome aberrations in metastatic ovarian cancer: relationship with abnormalities in primary tumors. Int J Cancer 45: 50-54
3. Bernett MJ, Blaber SI, Scarisbrick IA, Dhanarajan P, Thompson SM, Blaber M (2002) Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem 277: 24562-24570
4. Bharaj BB, Luo LY, Jung K, Stephan C, Diamandis EP (2002) Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. Prostate 51: 35-41
5. Borgono CA, Diamandis EP (2004) The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4: 876-890
6. Borgono CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth DH, Fracchioli S, Katsaros D, Diamandis EP (2003) Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 63: 9032-9041
7. Borgono CA, Michael IP, Diamandis EP (2004) Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2: 257-280
8. Chien CH, Wang FF, Hamilton TC (1994) Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells. Mol Cell Endocrinol 99: 11-19
9. Christophi GP, Isackson PJ, Blaber S, Blaber M, Rodriguez M, Scarisbrick IA (2004) Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J Neurochem 91: 1439-1449
10. Christopoulos TK, Diamandis EP (1992) Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 64: 342-346
11. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34: 181-220
12. Cramer SD, Chang BL, Rao A, Hawkins GA, Zheng SL, Wade WN, Cooke RT, Thomas LN, Bleecker ER, Catalona WJ, Sterling DA, Meyers DA, Ohar J, Xu J (2003) Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst 95: 1044-1053
13. Day Jr TG, Gallager HS, Rutledge FN (1975) Epithelial carcinoma of the ovary:prognostic importance of histologic grade. Natl Cancer Inst Monogr 42: 15-21
14. Diamandis EP, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, Nakamura T, Howarth DJ, Yamaguchi N (2002) Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 62: 295-300
15. Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman UH, Massobrio M, Van Der Zee AG, Vergote I, Katsaros D (2003) Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 21: 1035-1043
16. Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S, Sotiropoulou G (2000) Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem 33: 369-375
17. Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA (2003) Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res 9: 1710-1720
18. Dong Y, Kaushal A, Bui L, Chu S, Fuller PJ, Nicklin J, Samaratunga H, Clements JA (2001) Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 7: 2363-2371
19. Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618
20. Godwin AK, Testa JR, Hamilton TC (1993) The biology of ovarian cancer development. Cancer 71: 530-536
21. Hoffman BR, Katsaros D, Scorilas A, Diamandis P, Fracchioli S, Rigault de la Longrais IA, Colgan T, Puopolo M, Giardina G, Massobrio M, Diamandis EP (2002) Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br J Cancer 87: 763-771
22. Hoover R, Gray Sr LA, Fraumeni Jr JF (1977) Stilboestrol (diethylstilbestrol) and the risk of ovarian cancer. Lancet 2: 533-534
23. Jenkins RB, Bartelt Jr D, Stalboerger P, Persons D, Dahl RJ, Podratz K, Keeney G, Hartmann L (1993) Cytogenetic studies of epithelial ovarian carcinoma. Cancer Genet Cytogenet 71: 76-86
24. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
25. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J, Mysliwiec M, Schmitt M, Diamandis EP (2003) Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res 63: 2771-2774
26. Kruk PA, Auersperg N (1992) Human ovarian surface epithelial cells are capable of physically restructuring extracellular matrix. Am J Obstet Gynecol 167: 1437-1443
27. Kurlender L, Borgono C, Michael IP, Obiezu C, Elliott MB, Yousef GM, Diamandis EP (2005) A survey of alternative transcripts of human tissue kallikrein genes. Biochim Biophys Acta 1755: 1-14
28. Landry JR, Mager DL, Wilhelm BT (2003) Complex controls: the role of alternative promoters in mammalian genomes. Trends Genet 19: 640-648
29. Langdon SP, Hawkes MM, Lawrie SS, Hawkins RA, Tesdale AL, Crew AJ, Miller WR, Smyth JF (1990) Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br J Cancer 62: 213-216
30. Li Q, Harju S, Peterson KR (1999) Locus control regions: coming of age at a decade plus. Trends Genet 15: 403-408
31. Liu XL, Wazer DE, Watanabe K, Band V (1996) Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 56: 3371-3379
32. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, Van Gramberen M, De Bruijn H, Henrik A, Stenman UH, Massobrio M, Van Der Zee AG, Vergote I, Diamandis EP (2003) The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 63: 807-811
33. Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, Diamandis EP (2003) Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun 307: 948-955
34. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP (2001) The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 7: 806-811
35. Majumdar S, Diamandis EP (1999) The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines. Br J Cancer 79: 1594-1602
36. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170
37. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward DC (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 102: 7677-7682
38. Nelson PS, Gan L, Ferguson C, Moss P, Gelinas R, Hood L, Wang K (1999) Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci USA 96: 3114-3119
39. Ni X, Zhang W, Huang KC, Wang Y, Ng SK, Mok SC, Berkowitz RS, Ng SW (2004) Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 91: 725-731
40. Pampalakis G, Kurlender L, Diamandis EP, Sotiropoulou G (2004) Cloning and characterization of novel isoforms of the human kallikrein 6 gene. Biochem Biophys Res Commun 320: 54-61
41. Pejovic T, Heim S, Mandahl N, Baldetorp B, Elmfors B, Floderus UM, Furgyik S, Helm G, Himmelmann A, Willen H (1992) Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosomes Cancer 4: 58-68
42. Pejovic T, Heim S, Mandahl N, Elmfors B, Furgyik S, Floderus UM, Helm G, Willen H, Mitelman F (1991) Bilateral ovarian carcinoma: cytogenetic evidence of unicentric origin. Int J Cancer 47: 358-361
43. Petraki CD, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJ, Yousef GM, Diamandis EP (2001) The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem 49: 1431-1441
44. Pettersson F (1994) Annual Report on the Treatment in Gynecological Cancer. Stockholm: International Federation of Gynecology and Obstetrics
45. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J (1991) The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 5: 1921-1930
46. Scorilas A, Borgono CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP (2004) Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J Clin Oncol 22: 678-685
47. Serov SF, Scully RE, Sorbin LH (1973) Histological Typing of Ovarian Tumors. Geneva: World Health Organization
48. Smith MS, Lechago J, Wines DR, MacDonald RJ, Hammer RE (1992) Tissue-specific expression of kallikrein family transgenes in mice and rats. DNA Cell Biol 11: 345-358
49. Tanaka K, Boice CR, Testa JR (1989) Chromosome aberrations in nine patients with ovarian cancer. Cancer Genet Cytogenet 43: 1-14
50. Tsuyuki D, Grass L, Diamandis EP (1997) Frequent detection of mutations in the 50 flanking region of the prostate-specific antigen gene in female breast cancer. Eur J Cancer 33: 1851-1854
51. Whang-Peng J, Knutsen T, Douglass EC, Chu E, Ozols RF, Hogan WM, Young RC (1984) Cytogenetic studies in ovarian cancer. Cancer Genet Cytogenet 11: 91-106
52. Woolas RP, Conaway MR, Xu F, Jacobs IJ, Yu Y, Daly L, Davies AP, O'Briant K, Berchuck A, Soper JT (1995) Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 59: 111-116
53. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast Jr RC (1993) Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85: 1748-1751
54. Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA, Ingles SA (2000) Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 60: 839-841
55. Yousef GM, Diamandis EP (1999) The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation. J Biol Chem 274: 37511-37516
56. Yousef GM, Diamandis EP (2001) The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 22: 184-204
57. Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D (2001) Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res 61: 7811-7818
58. Yousef GM, Luo LY, Scherer SW, Sotiropoulou G, Diamandis EP (1999) Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics 62: 251-259
59. Yousef GM, Polymeris ME, Yacoub GM, Scorilas A, Soosaipillai A, Popalis C, Fracchioli S, Katsaros D, Diamandis EP (2003a) Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 63: 2223-2227
60. Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgono C, Rigault de la Longrais IA, Puopolo M, Massobrio M, Diamandis EP (2003b) Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol 21: 3119-3126
61. Zhang Z, Barnhill SD, Zhang H, Xu F, Yu Y, Jacobs I, Woolas RP, Berchuck A, Madyastha KR, Bast Jr RC (1999) Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 73: 56-61